RANZCR values professional input from members and regularly seeks member feedback on the development of professional documents, reports and submissions. When the College opens a consultation details and deadlines for submissions can be found following the links below.
The Royal Australian and New Zealand College of Radiologists (RANZCR) advocates for a national cancer screening program for Australia and New Zealand that responds to the changing needs within our communities and is effective, equitable and fully funded. RANZCR strongly supports the extension of the current national cancer screening program in both Australia and New Zealand to include lung cancer screening. The RANZCR Lung Cancer Screening Position Statement outlines the support of the College for a national lung cancer screening program across Australia and New Zealand, that is effective, equitable and fully funded.
Members and interested parties can submit their comments and feedback to This email address is being protected from spambots. You need JavaScript enabled to view it. COB 21 June 2021. Please reference line numbers where appropriate.
Clinical Radiology
RANZCR Lung Cancer Screening Position Statement
Telehealth has been defined by the International Organisation for Standardisation (ISO)1 and Standards Australia2 as “information and communication technologies (ICTs) to deliver healthcare services and transmit health information over long and short distances”. In radiation oncology, telehealth offers opportunity to improve professional support to regional services, outreach services and patient follow up³. Telehealth is vital to extending the benefits of multidisciplinary care to regional and rural patients and reducing the associated cost of care.
Members and interested parties can submit their comments and feedback to This email address is being protected from spambots. You need JavaScript enabled to view it. by COB 28th May 2021. Please reference line numbers where appropriate.
Radiation Oncology
Radiation Oncology Telehealth Principles
In BMD, a high level of attention should be afforded to quality control procedures in order to ensure that equipment is operating as precisely and accurately as possible. As part of this, precision testing – both in vitro and in vivo – should be standard clinical practice. Such testing is supported locally by the Guidelines1 (prepared by the College, ANZBMS, AANMS and ACPSEM), and internationally by the ISCD.
1Accreditation Guidelines for Bone Densitometry (March, 2003), found at: http://www.anzbms.org.au/resources/DXA/guide/densitometry_guidelines.pdf
Members and interested parties can submit their comments and feedback to This email address is being protected from spambots. You need JavaScript enabled to view it. by COB 29 June 2021. Please reference line numbers where appropriate.
MD in VIVO Short Term Precision Testing
Position Statements, Consultations and Submissions
Professional documents